AstraZeneca PLC

AstraZeneca PLC is a biopharmaceutical company focused on the discovery, development, manufacture, and commercialization of prescription medicines. Its portfolio includes drugs for oncology, cardiovascular, renal and metabolism, respiratory and immunology, vaccines and immune therapies, and rare diseases. Key products include Tagrisso, Imfinzi, Lynparza, and Calquence for cancer; Farxiga/Forxiga and Brilinta/Brilique for cardiovascular and metabolic conditions; Symbicort and Fasenra for respiratory and immunology; and Soliris and Ultomiris for rare diseases. The company also offers vaccines such as Fluenz/FluMist and Beyfortus. AstraZeneca serves primary and specialty care physicians through distributors and local representative offices globally.

AstraZeneca PLC is listed on the New York Stock Exchange (NYSE) under the ticker symbol AZN. Its shares trade in US dollars (USD). The company is headquartered in the United Kingdom, but its US-listed shares allow investors in the United States and other markets to trade in USD. This dual listing provides access to a broad investor base and facilitates trading in a major global currency.

AstraZeneca operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. This means it is a pharmaceutical company that develops, produces, and markets a wide range of prescription medications. The 'General' classification indicates that its product portfolio spans multiple therapeutic areas rather than being limited to a single specialty. AstraZeneca's focus includes oncology, cardiovascular, respiratory, immunology, and rare diseases, making it a diversified drug manufacturer.

AstraZeneca PLC is headquartered in the United Kingdom. It serves markets across the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. The company has a global presence, with local representative offices and distributors reaching primary and specialty care physicians worldwide. This extensive geographic footprint allows AstraZeneca to commercialize its medicines in both developed and emerging markets, addressing a wide range of healthcare needs globally.

AstraZeneca's portfolio includes numerous notable prescription medicines across various therapeutic areas. In oncology, key products are Tagrisso (lung cancer), Imfinzi (various cancers), Lynparza (ovarian, breast, pancreatic cancers), and Calquence (blood cancers). For cardiovascular and metabolic conditions, Farxiga/Forxiga (diabetes, heart failure) and Brilinta/Brilique (antiplatelet) are prominent. In respiratory and immunology, Symbicort (asthma, COPD) and Fasenra (severe asthma) are widely used. The company also offers rare disease treatments like Soliris and Ultomiris (paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome) and vaccines such as Fluenz/FluMist (influenza).